In This Article:
Knight Therapeutics (TSE:GUD) Full Year 2024 Results
Key Financial Results
-
Revenue: CA$371.3m (up 13% from FY 2023).
-
Net income: CA$4.33m (up from CA$16.8m loss in FY 2023).
-
Profit margin: 1.2% (up from net loss in FY 2023).
-
EPS: CA$0.043 (up from CA$0.16 loss in FY 2023).
GUD Post-Clinical Trial Products
-
Pre-registration: 7.
-
Launched (during full year): 4.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Knight Therapeutics Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) also surpassed analyst estimates.
The primary driver behind last 12 months revenue was the Brazil segment contributing a total revenue of CA$180.6m (49% of total revenue). Notably, cost of sales worth CA$196.9m amounted to 53% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to CA$53.9m (32% of total expenses). Explore how GUD's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company's shares are down 2.9% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Knight Therapeutics that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.